

821 Geary St. #4 San Francisco, CA 94109

May 6, 2021 Dear Dr. Colfax

We are a local community advocacy organization with concerns you have the power to address. It has come to our attention that your department works directly with the University of California, San Francisco. We have serious objections to the practices surrounding their fetal tissue experimentation projects currently taking place.

UCSF has multiple active projects that utilize the organs of pre-born children from elective abortions. As part of a grant contract with the National Institutes of Health, UCSF scientists were required to deliver two human fetuses per month over the course of 12 years for one project alone. The resulting studies, published by Dr. Cheryl Stoddart, noted that these fetuses were all the result of elective abortion procedures. They were between the ages of 18 and 24 weeks¹, meaning that many were viable and had up to a 68% chance of survival² outside their parents' uteruses. These fetuses would be transported to labs where their livers and thymuses were harvested and implanted into mice in order to create a humanized immune system for drug testing.

As an organization with a diverse membership base, we understand that the moral case against this research transcends political and ideological boundaries, and we are appalled that this has been permitted for such an extended period of time.

This research creates a perverse incentive for suppliers to prefer more inhumane methods of abortion. Since the use of digoxin would compromise the quality of the tissue, UCSF relies on either D&E abortions or medical induction³ without feticidal injections to secure this fetal tissue. This encourages UCSF and other suppliers to conduct elective abortions that are not only more painful for a pain-capable⁴ pre-born child but also more likely to result in a live birth. (Up to 50% of the time, such a procedure can result in live birth late in pregnancy.⁵)

Secondly, there are major questions around how useful this research actually is. The above humanized mouse project has never developed any meaningful therapeutics. Even if it did, it would still be the case that the same research could be accomplished with the tissue of miscarried children⁶ in certain circumstances. (Such research is more costly and poses greater logistical challenges, but it avoids the ethical implications of requiring aborted babies.) Another meaningful alternative for other studies is the use of organoids.⁷ For the project in question, it is possible to use surplus neonatal tissue⁸ to achieve the same end.

Science matters, but our pursuit of science must go hand-in-hand with a strong ethical grounding. Our values, and those of millions of other Americans, oppose the use of fetal tissue in research when such tissue comes from elective late-term abortions. We can work to create better, nonviolent ways of meeting medical research needs, such as tracking post-surgical thymus tissues from children born with an overabundance of such tissue. We can ensure the medical community is educated on ethical solutions. Such alternatives may be more challenging than research grounded in a regular supply of aborted fetus tissue.

As a progressive society, we need to be willing to absorb the shock of additional cost and logistical complications to protect the weakest among us. Ultimately, the case for tissue from late-term abortions is about convenience, not necessity. We look forward to a world where all science is human-centered and grounded in research methods that respect the bodily integrity of live human beings, and soon expect to hear back from you regarding our grievances.

Urgently,

The Pro-Life San Francisco team and concerned citizens across the City

- 1. Maidji, Ekaterina, et al. "Replication of CMV in the Gut of HIV-Infected Individuals and Epithelial Barrier Dysfunction." *PLOS Pathogens*, Public Library of Science, journals.plos.org/plospathogens/article?id=10.1371%2Fjournal.ppat.1006202#sec008.
- Manuck, Tracy A, et al. "Preterm Neonatal Morbidity and Mortality by Gestational Age: a Contemporary Cohort."
 American Journal of Obstetrics and Gynecology, U.S. National Library of Medicine, July 2016,
 www.ncbi.nlm.nih.gov/pmc/articles/PMC4921282/.
- 3. "Abortion after the First Trimester." *Innovating Education in Reproductive Health*, 13 July 2020, www.innovating-education.org/2016/05/abortion-first-trimester/.
- 4. Derbyshire SW, Bockmann JC. Reconsidering fetal pain. Journal of Medical Ethics 2020;46:3-6.
- 5. "Labor Induction Abortion In The Second Trimester." www.contraceptionjournal.org/article/S0010-7824(11)00057-6/fulltext.
- 6. Lee, Tara Sander. "Written Testimony of Tara Sander Lee, Ph.D., in Support of Ethical Alternatives to Aborted Fetal Tissue Research." *Charlotte Lozier Institute*, lozierinstitute.org/written-testimony-of-tara-sander-lee-ph-d-in-support-of-ethical-alternatives-to-aborted-fetal-tiss ue-research/.
- 7. "Organoids: Modeling Development and the Stem Cell Niche in a Dish." www.cell.com/developmental-cell/fulltext/S1534-5807(16)30589-5.
- 8. Brown ME;Zhou Y;McIntosh BE;Norman IG;Lou HE;Biermann M;Sullivan JA;Kamp TJ;Thomson JA;Anagnostopoulos PV;Burlingham WJ; "A Humanized Mouse Model Generated Using Surplus Neonatal Tissue." *Stem Cell Reports*, U.S. National Library of Medicine, pubmed.ncbi.nlm.nih.gov/29576539/.